Integra Lifesciences Holdings Stock Performance
| IART Stock | USD 24.12 0.60 2.43% |
The company retains a Market Volatility (i.e., Beta) of 1.61, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Integra LifeSciences will likely underperform. Integra LifeSciences right now retains a risk of 2.8%. Please check out Integra LifeSciences potential upside, as well as the relationship between the kurtosis and price action indicator , to decide if Integra LifeSciences will be following its current trending patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Integra LifeSciences Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Integra LifeSciences is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 12.11 | Five Day Return 11.8 | Year To Date Return 7.38 | Ten Year Return (15.10) | All Time Return 434.49 |
Last Split Factor 2:1 | Last Split Date 2017-01-04 |
1 | Disposition of 2561 shares by Lea Knight of Integra LifeSciences at 28.73 subject to Rule 16b-3 | 11/29/2024 |
2 | Disposition of 1700 shares by Michael McBreen of Integra LifeSciences at 24.155 subject to Rule 16b-3 | 12/02/2024 |
3 | Disposition of 4070 shares by Eric Schwartz of Integra LifeSciences at 24.595 subject to Rule 16b-3 | 12/03/2024 |
4 | Gentex Signs Definitive Agreement to Acquire VOXX International | 12/18/2024 |
5 | Regenerative Medicine Market Size to Hit USD 235.98 Billion by 2032, Driven by Advancements in Cell Therapy and Stem Cells SNS Insider | 01/08/2025 |
6 | Moran CHIPS offer is on the table for recently acquired Integra Technologies | 01/28/2025 |
7 | Idaho SPEED to benefit Integra | 01/30/2025 |
8 | These 4 Measures Indicate That Integra LifeSciences Holdings Is Using Debt Extensively - Simply Wall St | 01/31/2025 |
9 | Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference ... | 02/04/2025 |
10 | Integra Essentia Third Quarter 2025 Earnings EPS 0.013 | 02/12/2025 |
11 | Board presenta i nuovi prodotti Foresight e Signals rivoluzionando la pianificazione aziendale con AI e intelligenza economica | 02/19/2025 |
12 | SHAREHOLDER ALERT Potential Recovery for Integra LifeSciences Holdings Corporation Investors Affected by Stock Drop - Levi Korsinsky Pursuing Class Action Lawsu... | 02/21/2025 |
13 | Integra LifeSciences Stock Rises on Strong Q4 Results | 02/25/2025 |
| Begin Period Cash Flow | 456.7 M |
Integra |
Integra LifeSciences Relative Risk vs. Return Landscape
If you would invest 2,458 in Integra LifeSciences Holdings on November 28, 2024 and sell it today you would lose (46.00) from holding Integra LifeSciences Holdings or give up 1.87% of portfolio value over 90 days. Integra LifeSciences Holdings is currently generating 0.0059% in daily expected returns and assumes 2.7995% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Integra, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Integra LifeSciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Integra LifeSciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Integra LifeSciences Holdings, and traders can use it to determine the average amount a Integra LifeSciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0021
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IART |
Estimated Market Risk
| 2.8 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Integra LifeSciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Integra LifeSciences by adding Integra LifeSciences to a well-diversified portfolio.
Integra LifeSciences Fundamentals Growth
Integra Stock prices reflect investors' perceptions of the future prospects and financial health of Integra LifeSciences, and Integra LifeSciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Integra Stock performance.
| Return On Equity | -0.0042 | ||||
| Return On Asset | 0.0311 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 3.41 B | ||||
| Shares Outstanding | 77.16 M | ||||
| Price To Earning | 26.94 X | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 1.22 X | ||||
| Revenue | 1.54 B | ||||
| Gross Profit | 932.52 M | ||||
| EBITDA | 274.01 M | ||||
| Net Income | 67.74 M | ||||
| Cash And Equivalents | 451.52 M | ||||
| Cash Per Share | 5.41 X | ||||
| Total Debt | 1.68 B | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 3.85 X | ||||
| Book Value Per Share | 19.73 X | ||||
| Cash Flow From Operations | 139.96 M | ||||
| Earnings Per Share | (0.09) X | ||||
| Market Capitalization | 1.91 B | ||||
| Total Asset | 3.78 B | ||||
| Retained Earnings | 946.86 M | ||||
| Working Capital | 751.06 M | ||||
| Current Asset | 438.5 M | ||||
| Current Liabilities | 139.13 M | ||||
About Integra LifeSciences Performance
Assessing Integra LifeSciences' fundamental ratios provides investors with valuable insights into Integra LifeSciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Integra LifeSciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 195.94 | 170.42 | |
| Return On Capital Employed | 0.01 | 0.01 |
Things to note about Integra LifeSciences performance evaluation
Checking the ongoing alerts about Integra LifeSciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Integra LifeSciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Integra LifeSciences has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Integra LifeSciences Stock Rises on Strong Q4 Results |
- Analyzing Integra LifeSciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Integra LifeSciences' stock is overvalued or undervalued compared to its peers.
- Examining Integra LifeSciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Integra LifeSciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Integra LifeSciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Integra LifeSciences' stock. These opinions can provide insight into Integra LifeSciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.